Mario Sznol

Mario Sznol, MD is a Professor of Medicine (Medical Oncology) at Yale School of Medicine, Clinical Research Leader of the Melanoma Program, and Co-Director of the Yale SPORE in Skin Cancer. He is also co-director of the Cancer Immunology Program at Yale Cancer Center. Previously with the National Cancer Institute, Dr. Sznol has developed an international reputation in cancer drug development.

His educational background includes:

• BA from Rice University (1979)
• MD from Baylor College of Medicine (1982)
• Residency at Baylor College of Medicine (1985)
• Fellowship at Mount Sinai College of Medicine (1987)

Dr. Sznol's research focuses on cancer immunotherapy, drug development for cancer, and the treatment of patients with melanoma and renal cell carcinoma. He actively works to expand clinical trial opportunities at Yale Cancer Center, particularly those focusing on immunotherapy and novel agents. His work spans both clinical trials and translational research to better understand immunotherapy mechanisms and resistance patterns.

His recent publications demonstrate a strong emphasis on immunotherapy outcomes for melanoma and kidney cancers, with particular attention to treatment combinations, biomarkers of response, and end-of-life considerations in the immunotherapy era. His collaborative network includes prominent Yale researchers such as Dr. Harriet Kluger, Dr. Ruth Halaban, and Dr. Lucia Jilaveanu.

Notable professional contributions:

• Co-Director of the Yale SPORE in Skin Cancer
• Principal Investigator for multiple melanoma clinical trials
• Extensive publication record in high-impact oncology journals
• Active role in Yale's immuno-oncology training programs

As a clinician, Dr. Sznol sees patients with melanoma and kidney cancers at Yale Medicine, emphasizing honest communication about disease, treatment options, and expected outcomes. His team at Smilow Cancer Hospital provides comprehensive support throughout the treatment process.

Dr. Sznol is actively involved in mentoring through Yale's educational programs, including the K12 Calabresi Immuno-Oncology Training Program, contributing to the development of the next generation of oncology researchers and clinicians.